EMA’s CHMP upholds its negative opinion on masitinib for ALS
An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB…
Articles by Margarida Maia, PhD
First SOD1-ALS patient dosed in trial of AMT-162 gene therapy
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development…
NeuroSense moving to request early approval of PrimeC in Canada
NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating…
FGF4 shows benefits in ALS but fails to protect motor neurons
A growth factor called FGF4 can reduce the activity of astrocytes — star-shaped cells in the brain and spinal cord…
Phase 1 trial of prosetin to create digital twins of ALS patients
ProJenX has teamed up with Unlearn, a company that specializes in artificial intelligence (AI), to create…
MDA $500K research grant will support HEALEY ALS platform trial
The Muscular Dystrophy Association (MDA) has awarded a $500,000 research grant to a Massachusetts General Hospital scientist to support…
Higher risk of ALS found with rare gene variants tied to Parkinson’s
Certain rare genetic variants associated with Parkinson’s disease and other neurodegenerative disorders may increase, by up to nearly four…
First group of healthy volunteers dosed in QRL-101 MAD study
Quralis has completed dosing in the first group of healthy adults who volunteered for its Phase 1 clinical trial…
FDA clears Phase 1 testing of NDC-011 dual combination ALS therapy
The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase…
Targeting 3 cell types at same time seen to extend survival in ALS mice
A strategy that simultaneously targets motor neurons, astrocytes, and microglia — three cell types involved in the development and progression…